Editas Medicine Inc
$ 3.37
-0.59%
15 Apr - close price
- Market Cap 331,786,000 USD
- Current Price $ 3.37
- High / Low $ 3.58 / 3.33
- Stock P/E N/A
- Book Value 0.28
- EPS -1.80
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -1.98 %
- 52 Week High 4.54
- 52 Week Low 1.23
About
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$5.72
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-10 | 2025-08-12 | 2025-05-06 | 2025-02-26 | 2024-11-01 | 2024-08-07 | 2024-05-08 | 2024-02-28 | 2023-11-03 | 2023-08-02 | 2023-05-05 |
| Reported EPS | -0.06 | -0.28 | -0.63 | -0.92 | -0.55 | -0.75 | -0.82 | -0.76 | -0.23 | -0.55 | -0.56 | -0.71 |
| Estimated EPS | -0.2302 | -0.3 | -0.4 | -0.66 | -0.3286 | -0.75 | -0.7 | -0.66 | -0.54 | -0.57 | -0.76 | -0.78 |
| Surprise | 0.1702 | 0.02 | -0.23 | -0.26 | -0.2214 | 0 | -0.12 | -0.1 | 0.31 | 0.02 | 0.2 | 0.07 |
| Surprise Percentage | 73.9357% | 6.6667% | -57.5% | -39.3939% | -67.3767% | 0% | -17.1429% | -15.1515% | 57.4074% | 3.5088% | 26.3158% | 8.9744% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EDIT
2026-04-14 02:39:21
Editas Medicine, Inc. (NASDAQ:EDIT) has an average "Moderate Buy" rating from analysts, with an average 1-year price target of $5.30. Institutional investors, including Renaissance Technologies and UBS, have significantly increased their positions, indicating strong investor confidence. Despite recent quarterly earnings beating expectations, the company remains unprofitable, with a negative net margin and projected negative EPS for the current year.
2026-04-11 06:09:27
Wall Street Zen has downgraded Editas Medicine (NASDAQ:EDIT) from a "hold" to a "sell" rating. Despite better-than-expected Q4 earnings with an EPS of $(0.06) and revenue of $24.74 million, the company remains unprofitable with a negative return on equity and net margin. Analysts for the current fiscal year forecast an EPS of -2.71, though the overall consensus rating for the stock is a "Moderate Buy" with an average price target of $5.30.
2026-04-08 18:09:31
Editas Medicine, Inc. (NASDAQ: EDIT) has announced a change in its independent auditor, dismissing Ernst & Young LLP and appointing PricewaterhouseCoopers LLP (PwC) for the fiscal year ending December 31, 2026. This decision followed a formal review process by the Audit Committee, with no disagreements or "reportable events" cited between Editas and Ernst & Young. The company emphasized that this transition is a part of normal corporate oversight rather than a response to financial reporting concerns.
2026-04-08 15:30:00
Editas Medicine (EDIT) shares have risen 3.8% since its last earnings report, outperforming the S&P 500. The company reported a narrower-than-expected Q4 2025 loss and increased full-year revenues, primarily due to reduced operating expenses after discontinuing the reni-cel program. While estimates have shown an upward trend, indicating promise, the stock currently holds a Zacks Rank #3 (Hold) with an aggregate VGM Score of F.
2026-04-07 21:42:18
Editas Medicine announced the dismissal of Ernst & Young LLP as its independent registered public accounting firm, effective April 1, 2026, and has appointed PricewaterhouseCoopers LLP (PwC) as the new auditor for the fiscal year ending December 31, 2026. The decision followed a formal review, with Editas Medicine confirming no disagreements or reportable events with Ernst & Young. This change comes shortly after Editas Medicine reported strong fourth-quarter financial results and significant pipeline advancements.
2026-04-07 20:39:53
Editas Medicine (NASDAQ: EDIT) has appointed PricewaterhouseCoopers LLP (PwC) as its new independent registered public accounting firm for the fiscal year ending December 31, 2026, dismissing Ernst & Young LLP. This decision followed a formal review process, with no disagreements or reportable events noted between Editas Medicine and Ernst & Young. The company also reported strong fourth-quarter financial results, exceeding analyst expectations.
